Thymosin‐β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma

Thymosin‐β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma

Abstract Retinoids are an important component of neuroblastoma therapy at the stage of minimal residual disease, yet 40–50% of patients treated with 13‐cis‐retinoic acid (13‐cis‐RA) still relapse, indicating the need for more effective retinoid therapy. Vorinostat, or Suberoylanilide hydroxamic acid...

Full description

Saved in:
Bibliographic Details
Main Authors: Belamy B. Cheung, Owen Tan, Jessica Koach, Bing Liu, Michael S.Y. Shum, Daniel R. Carter, Selina Sutton, Sela T. Po'uha, Louis Chesler, Michelle Haber, Murray D. Norris, Maria Kavallaris, Tao Liu, Geraldine M. O'Neill, Glenn M. Marshall
Format: Article
Language:English
Published: Wiley 2015-08-01
Series:Molecular Oncology
Subjects:
Thymosin-β4 (Tβ4)
4-HPR
SAHA
Neuroblastoma
Histone deacetylase inhibitors and retinoic acid receptor alpha (RARα)
Online Access:https://doi.org/10.1016/j.molonc.2015.04.005
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items